Drug Research

Early-stage pharmaceutical companies invest heavily in discovery and development without knowing whether a candidate will reach clinical trials and commercialization. This uncertainty makes every spending decision critical, particularly when laboratory equipment represents substantial expenses across analytical testing and sample...

Danish pharmaceutical company Novo Nordisk and biotechnology developer Orbis Medicines have entered into a drug discovery and licensing agreement valued at up to $1.4 billion to develop oral therapies for cardiometabolic diseases. The program aims to advance oral alternatives...

Senior officials at the US Food and Drug Administration have signaled that the agency is open to novel and innovative approaches in the clinical development of psychedelic drugs, citing the worsening mental health crisis across the United States. The...

Gilead Sciences has expanded its R&D infrastructure with a new 182,000-square-foot facility in Foster City dedicated to inflammation, oncology, and data science.

Boehringer Ingelheim has joined other pharmaceutical leaders in deploying Owkin's agentic AI scientist, K Pro, to analyze multimodal patient data in oncology and immunology R&D.

The European Medicines Agency has launched a voluntary framework for sharing data from non-animal testing methods to build regulatory confidence and refine drug development.

The pharmaceutical industry currently faces a significant challenge regarding the consistency of experimental results, a phenomenon often referred to as the reproducibility crisis. Central to this issue is the variability of biological reagents, particularly antibodies, which are fundamental tools...